“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
By Jeff Mason and Carl O’Donnell
(Reuters) – The United States reached an agreement with drug manufacturer Modern Inc to obtain a hundred million doses of its possible COVID-19 vaccine for about $1.5 billion (1.15 billion pounds), the company and the White House said Tuesday.
The United States has reached agreements in recent weeks to obtain loads of millions of doses of COVID-19 vaccines from several corporations as a component of its Operation Warp Speed program, which aims to deliver a vaccine to the country until the end of the year.
The value according to the dosage of Moderna is approximately $30.50 consistent with the user for a two-dose diet.
With the exception of its agreement with AstraZeneca, which presented a consistent decrease in value with the drug in exchange for initial studies and progression costs, all COVID-19 vaccines are worth between $20 and $42 for a two-dose treatment.
Moderna’s candidate vaccine, mRN-1273, is one of the few that has already reached the final phase and is expected to be completed in September, the company said this month.
Moderna’s agreement with the United States will be paid in full only if the drug manufacturer reaches certain non-specific schedules for vaccine delivery.
The United States has entered into acquisition agreements with Johnson-Johnson, AstraZeneca Plc, Pfizer Inc and BioNTech SE, and Sanofi SA and GlaxoSmithKline Plc for their respective candidate vaccines.
The agreements would block more than 500 million doses of the COVID-19 vaccine for the United States, assuming that the corporations involved get regulatory approval. Some transactions also give the U.S. The ability to acquire more doses.
In the past, the U.S. government He had given Moderna about $1 billion to fund his research efforts, which raised overall U.S. investment. About $2.5 billion.
Other countries, besides Japan, the United Kingdom and Canada, have agreements with drug manufacturers.
(Report through Jeff Mason and Carl O’Donnell; Editing via Peter Henderson, Chris Reese and Tom Brown)